scispace - formally typeset
D

David Walk

Researcher at University of Minnesota

Publications -  71
Citations -  3112

David Walk is an academic researcher from University of Minnesota. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Medicine. The author has an hindex of 21, co-authored 62 publications receiving 2542 citations. Previous affiliations of David Walk include Mayo Clinic & Eli Lilly and Company.

Papers
More filters
Journal ArticleDOI

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Aude Nicolas, +435 more
- 21 Mar 2018 - 
TL;DR: Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia and Charcot-Marie-Tooth type 2.
Journal ArticleDOI

Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus.

TL;DR: Quantitative sensory testing (QST) is a psychophysical method used to quantify somatosensory function in response to controlled stimuli in healthy subjects and patients as discussed by the authors, which has not gained a large acceptance among clinicians for many reasons, and in significant part because of the lack of information about standards for performing QST, its potential utility and interpretation of results.
Journal ArticleDOI

Characteristics of motor unit discharge in subjects with hemiparesis

TL;DR: In 3 of the 6 subjects, there were significant reductions in mean discharge rate of motor units in the paretic muscle, which could potentially alter the precise match of motoneuron properties to the mechanical properties of the innerved muscle fibers, and reduce the efficiency of muscle contraction.
Journal ArticleDOI

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, +149 more
- 01 Jan 2018 - 
TL;DR: This study, which is to the authors' knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting thatSCIg can be used as a maintenance treatment for C IDP.
Journal ArticleDOI

A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.

TL;DR: The results help predict the long-term safety of NGX-4010 applications in patients by evaluating the effect of a single 60-minute application on ENF density and QST in healthy volunteers followed for 24 weeks.